Optimizing procedural efficiency and kidney function assessment for patients on SGLT2 inhibitors

Navn på bevillingshaver

Esben Iversen


Postdoctoral Fellow


Northwell Health, New York, United States


DKK 1,120,000




Internationalisation Fellowships


The overall aim of this project is to improve routine clinical care for patients on SGLT2 inhibitors. This will be explored in three sub-studies, each focusing on the utility of a simple biomarker to optimize procedural efficiency or kidney function assessment.


SGLT2 inhibitors are a relatively new class of antidiabetic medications used to treat type 2 diabetes mellitus. Use of SGLT2 inhibitors has expanded in recent years due to evidence of other benefits like cardiorenal protection. However, this expanded use poses unique challenges to routine clinical care, such as frequent procedure cancellations and inaccurate kidney function assessment.


First, I will investigate how point-of-care ketones can be used to evaluate perioperative risk of diabetic ketoacidosis. Second, I will measure how SGLT2 inhibitors impact the accuracy of kidney function assessment. Third, I will determine whether suPAR, a biomarker of systemic inflammation, can predict the effect of SGLT2 inhibitors on filtration markers used to estimate kidney function.

Tilbage til oversigtssiden